Although PTCs rarely behave as aggressive tumors, a point mutation in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) (encoding a serine-threonine kinase that is a constituent of the MAPK pathway), namely, BRAF V600E, which accounts for 30–70% of mutations in all PTCs, has been linked to extra-thyroidal extension and lymph node metastasis [8,11,12,13]. Here, BRAF is linked to metastatic malignant neoplasm in the lymph nodes.